review_heavy
Review literature is very dense relative to primary central evidence.
supportedtopmoderate inflation risk
Bacteroides fragilis
colorectal cancer
Bacteroides fragilis looks like a credible signal in colorectal cancer, though some caution is still warranted.
Bacteroides fragilis shows a moderate evidence base in colorectal cancer, with multiple central papers and additional supporting literature.
bacteroides_fragilis
Credibility score
70
Human translation
3/5
Reproducibility
5/5
Novelty
1/5
Actionability
3/5
Credibility 70Human translation 3/5Reproducibility 5/5Novelty 1/5Actionability 3/5
Why this scores the way it does
- moderate central evidence base
- dense review literature
- substantial preclinical support
Main caveats
- directionality and confounding still require curated review
Internal review flags
1 flagsPrimary central evidence
14 papersAnalysis of Fusobacterium persistence and antibiotic response in colorectal cancer.
2017Science (New York, N.Y.)
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Tumour-associated and non-tumour-associated microbiota: Addendum.
2018Gut microbes
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria.
2018Science (New York, N.Y.)
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Gegen Qinlian decoction enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by remodelling the gut microbiota and the tumour microenvironment.
2019Cell death & disease
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
A novel faecal Lachnoclostridium marker for the non-invasive diagnosis of colorectal adenoma and cancer.
2020Gut
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Enterotoxigenic Bacteroidesfragilis Promotes Intestinal Inflammation and Malignancy by Inhibiting Exosome-Packaged miR-149-3p.
2021Gastroenterology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Gut microbiota-mediated nucleotide synthesis attenuates the response to neoadjuvant chemoradiotherapy in rectal cancer.
2023Cancer cell
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Bile salt hydrolase in non-enterotoxigenic Bacteroides potentiates colorectal cancer.
2023Nature communications
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Analysis of differences in intestinal flora associated with different BMI status in colorectal cancer patients.
2024Journal of translational medicine
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Microbiota in colorectal cancer related to liver metastasis.
2024Chinese journal of cancer research = Chung-kuo yen cheng yen chiu
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Clinicopathological, molecular, and prognostic features of colorectal carcinomas with KRAS c.34G>T (p.G12C) mutation.
2024Cancer science
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Gut microbiome model predicts response to neoadjuvant immunotherapy plus chemoradiotherapy in rectal cancer.
2024Med (New York, N.Y.)
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
An Empirical Dietary Pattern Associated With the Gut Microbial Features in Relation to Colorectal Cancer Risk.
2024Gastroenterology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
KAJF alleviated colorectal cancer liver metastasis by reshaping the gut microbiota and inhibiting M2-like macrophage polarization.
2025Phytomedicine : international journal of phytotherapy and phytopharmacology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Preclinical supporting evidence
11 papers[Carcinogenesis and Gut Microbiota].
2019Gan to kagaku ryoho. Cancer & chemotherapy
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Fecal Microbiota Transplantation (FMT) Alleviates Experimental Colitis in Mice by Gut Microbiota Regulation.
2020Journal of microbiology and biotechnology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Intratumoral presence of the genotoxic gut bacteria pks+ E. coli, Enterotoxigenic Bacteroides fragilis, and Fusobacterium nucleatum and their association with clinicopathological and molecular features of colorectal cancer.
2024British journal of cancer
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Consistent signatures in the human gut microbiome of old- and young-onset colorectal cancer.
2024Nature communications
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Association between gut microbiota and CpG island methylator phenotype in colorectal cancer.
2024Gut microbes
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Disruption of the intestinal clock drives dysbiosis and impaired barrier function in colorectal cancer.
2024Science advances
Disease-relevant preclinical or model-based paper useful as supporting evidence.
A highly conserved SusCD transporter determines the import and species-specific antagonism of Bacteroides ubiquitin homologues.
2024Nature communications
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Dietary fibre counters the oncogenic potential of colibactin-producing Escherichia coli in colorectal cancer.
2025Nature microbiology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Bacteroides fragilis promotes chemoresistance in colorectal cancer, and its elimination by phage VA7 restores chemosensitivity.
2025Cell host & microbe
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Microbial riboflavin inhibits ceramide synthase 3 to lower ceramide (d18:1/26:0) and delay colorectal cancer progression.
2025Cell metabolism
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Microbiota utilization of intestinal amino acids modulates cancer progression and anticancer immunity.
2026Cell host & microbe
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Review supporting evidence
36 papersBacterial oncogenesis in the colon.
2013Future microbiology
Relevant review or meta-analysis for the signal-disease area.
Gut microbiota imbalance and colorectal cancer.
2016World journal of gastroenterology
Relevant review or meta-analysis for the signal-disease area.
Gut Microbiota, Inflammation, and Colorectal Cancer.
2016Annual review of microbiology
Relevant review or meta-analysis for the signal-disease area.
Colorectal Carcinoma: A General Overview and Future Perspectives in Colorectal Cancer.
2017International journal of molecular sciences
Relevant review or meta-analysis for the signal-disease area.
Food, microbiome and colorectal cancer.
2018Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
Relevant review or meta-analysis for the signal-disease area.
Intestinal microbiota, chronic inflammation, and colorectal cancer.
2018Intestinal research
Relevant review or meta-analysis for the signal-disease area.
Gut microbiota in colorectal cancer: mechanisms of action and clinical applications.
2019Nature reviews. Gastroenterology & hepatology
Relevant review or meta-analysis for the signal-disease area.
The Four Horsemen in Colon Cancer.
2019Journal of oncology
Relevant review or meta-analysis for the signal-disease area.
Role of the intestinal microbiome in colorectal cancer surgery outcomes.
2019World journal of surgical oncology
Relevant review or meta-analysis for the signal-disease area.
Bacterial biofilm in colorectal cancer: What is the real mechanism of action?
2020Microbial pathogenesis
Relevant review or meta-analysis for the signal-disease area.
Gallstone Disease and Microbiome.
2020Microorganisms
Relevant review or meta-analysis for the signal-disease area.
Microbiota Effects on Carcinogenesis: Initiation, Promotion, and Progression.
2021Annual review of medicine
Relevant review or meta-analysis for the signal-disease area.
The Intestinal Microbiota and Colorectal Cancer.
2020Frontiers in immunology
Relevant review or meta-analysis for the signal-disease area.
Gut microbiota-derived metabolites in CRC progression and causation.
2021Journal of cancer research and clinical oncology
Relevant review or meta-analysis for the signal-disease area.
Tumorigenic bacteria in colorectal cancer: mechanisms and treatments.
2021Cancer biology & medicine
Relevant review or meta-analysis for the signal-disease area.
The gastrointestinal microbiota in colorectal cancer cell migration and invasion.
2021Clinical & experimental metastasis
Relevant review or meta-analysis for the signal-disease area.
Microbe-based management for colorectal cancer.
2021Chinese medical journal
Relevant review or meta-analysis for the signal-disease area.
Carcinogenic microbiota and its role in colorectal cancer development.
2022Seminars in cancer biology
Relevant review or meta-analysis for the signal-disease area.
Colorectal cancer: the facts in the case of the microbiota.
2022The Journal of clinical investigation
Relevant review or meta-analysis for the signal-disease area.
Microbiome and colorectal carcinogenesis: Linked mechanisms and racial differences.
2022World journal of gastrointestinal oncology
Relevant review or meta-analysis for the signal-disease area.
Effect of gut microbiota in the colorectal cancer and potential target therapy.
2022Discover oncology
Relevant review or meta-analysis for the signal-disease area.
Meta-Analysis of Altered Gut Microbiota Reveals Microbial and Metabolic Biomarkers for Colorectal Cancer.
2022Microbiology spectrum
Relevant review or meta-analysis for the signal-disease area.
Intestinal phages interact with bacteria and are involved in human diseases.
2022Gut microbes
Relevant review or meta-analysis for the signal-disease area.
Gut microbiota, inflammatory bowel disease and colorectal cancer.
2022World journal of gastroenterology
Relevant review or meta-analysis for the signal-disease area.
Microbiota Dysbiosis a Cause of Colorectal Cancer or Not? A Systematic Review.
2022Cureus
Relevant review or meta-analysis for the signal-disease area.
Gut Microbiota in Colorectal Cancer: Biological Role and Therapeutic Opportunities.
2023Cancers
Relevant review or meta-analysis for the signal-disease area.
Intestinal bacteria and colorectal cancer: etiology and treatment.
2023Gut microbes
Relevant review or meta-analysis for the signal-disease area.
Role of the Gut Microbiota and Its Metabolites in Tumorigenesis or Development of Colorectal Cancer.
2023Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Relevant review or meta-analysis for the signal-disease area.
Colorectal cancer and gut microbiota studies in China.
2023Gut microbes
Relevant review or meta-analysis for the signal-disease area.
Crosstalk between gut microbiota and metastasis in colorectal cancer: implication of neutrophil extracellular traps.
2023Frontiers in immunology
Relevant review or meta-analysis for the signal-disease area.
Gut Microbiota and Colorectal Cancer: A Balance Between Risk and Protection.
2025International journal of molecular sciences
Relevant review or meta-analysis for the signal-disease area.
Intestinal dysbiosis and colorectal cancer.
2025Chinese medical journal
Relevant review or meta-analysis for the signal-disease area.
Emerging New Treatments for Colon Cancer.
2025Current medicinal chemistry
Relevant review or meta-analysis for the signal-disease area.
Harnessing gut microbiota for colorectal cancer therapy: from clinical insights to therapeutic innovations.
2025NPJ biofilms and microbiomes
Relevant review or meta-analysis for the signal-disease area.
Potential Pathogens Associated with Colorectal Cancer.
2025Current pharmaceutical biotechnology
Relevant review or meta-analysis for the signal-disease area.
Gut microbiota and diet in colorectal cancer: Converging determinants of carcinogenesis.
2026Gut microbes
Relevant review or meta-analysis for the signal-disease area.